-
11.21.2019 | T2 Biosystems wins CE Mark approval for diagnostic blood panel
T2 Biosystems (NSDQ:TTOO) this week said it received CE mark approval for its T2Resistance Panel designed to detect 13 drug resistance genes in a blood sample.
-
09.13.2019 | T2 Biosystems jumps on $69m BARDA deal
Lexington, Mass.-based T2 Biosystems signed a maximum $69 million funding deal with the Health and Human Services Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research & Development Authority for the development of its MR-based diagnostic for sepsis-causing pathogens and antibiotic-resistance genes.
-
03.01.2019 | T2 Biosystems: FDA Grants breakthrough device designation for the T2Resistance Panel
The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the T2Resistance Panel, a diagnostic tool that detects resistance markers from a single patient blood sample.
Toggle navigation